The Utility of Biomarkers for Risk Stratification in Barrett’s Esophagus

Abstract

Challenges remain to determine which patients with Barrett’s esophagus with no dysplasia or low-grade dysplasia would benefit from therapy or tailored surveillance intervals. Biomarkers have the potential to improve risk stratification in Barrett’s esophagus through predictive capability and ease of use. We highlight biomarkers investigated in risk stratification in Barrett’s esophagus including p53 aberrancy, chromosomal derangements, immunofluorescence-based panels, and DNA methylation panels. We explore non-endoscopic approaches that may be implemented in the office-based setting and discuss the utility of sample collection in patients with Barrett’s esophagus and in the broader population.